Top Page
Clarity Pharmaceuticals Ltd.
(Sydney:CU6)
Clarity Pharmaceuticals Ltd. (CU6) vs. iShares MSCI Australia ETF (EWA)
Clarity Pharmaceuticals Ltd. Business Overview & Revenue Model
Clarity Pharmaceuticals Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.46M | 9.46M | 11.51M | 9.80M | 6.46M | 3.20M |
| Gross Profit | 9.46M | 9.46M | 11.51M | 9.70M | 6.41M | 3.18M |
| EBITDA | -68.91M | -68.91M | -44.65M | -34.20M | -30.15M | -13.38M |
| Net Income | -64.30M | -64.30M | -42.32M | -24.60M | -23.75M | -10.22M |
Balance Sheet | ||||||
| Total Assets | 101.17M | 101.17M | 154.63M | 76.90M | 99.82M | 22.61M |
| Cash, Cash Equivalents and Short-Term Investments | 84.12M | 84.12M | 136.51M | 65.01M | 92.34M | 18.94M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 10.94M | 10.94M | 8.33M | 7.72M | 7.59M | 2.34M |
| Stockholders Equity | 90.23M | 90.23M | 146.30M | 69.18M | 92.24M | 20.28M |
Cash Flow | ||||||
| Free Cash Flow | -54.95M | -54.95M | -43.74M | -27.55M | -13.53M | -7.74M |
| Operating Cash Flow | -54.77M | -54.77M | -43.24M | -27.50M | -13.31M | -7.68M |
| Investing Cash Flow | 51.99M | 51.99M | -55.31M | 3.15M | -26.71M | -60.31K |
| Financing Cash Flow | 2.21M | 2.21M | 115.21M | 231.58K | 86.93M | 10.91M |
Clarity Pharmaceuticals Ltd. Technical Analysis
Clarity Pharmaceuticals Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | AU$591.87M | 16.32 | 15.90% | 0.38% | 7.76% | 1.55% | |
67 Neutral | $3.43B | 203.41 | 3.21% | ― | 60.23% | -66.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$1.41B | -15.27 | -40.23% | ― | ― | -5.70% | |
49 Neutral | AU$567.38M | -9.00 | -35.86% | ― | ― | -19.21% | |
47 Neutral | AU$226.56M | -2.56 | -90.93% | ― | 456.50% | -457.14% | |
46 Neutral | AU$1.04B | -14.38 | -54.37% | ― | ― | -29.93% |
Clarity Pharmaceuticals Ltd. Corporate Events
Clarity Pharmaceuticals reported a strong cash position of $226.2 million as of 31 December 2025, underpinning its ability to advance multiple late-stage clinical programs. In its SECuRE Phase II trial of 67Cu-SAR-bisPSMA for prostate cancer, an interim review by the Safety Review Committee supported continuation without protocol changes, with data showing a favourable safety profile and promising efficacy, including substantial PSA reductions in all evaluable patients and one case of undetectable disease on imaging. The Co-PSMA investigator-initiated trial demonstrated that 64Cu-SAR-bisPSMA detected significantly more PSMA-positive lesions than the current standard-of-care 68Ga-PSMA-11 PET/CT in patients with biochemical recurrence and low PSA, reinforcing the competitive potential of Clarity’s diagnostic platform. Additionally, following a successful End-of-Phase meeting with the US FDA, Clarity is set to begin a pivotal Phase III registrational trial of its 64Cu-SARTATE diagnostic agent in neuroendocrine tumours in 2026, marking a key step toward potential regulatory approval and commercial entry in this indication.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$3.50 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
Clarity Pharmaceuticals announced that its SECuRE Phase II Cohort Expansion trial of 67Cu-SAR-bisPSMA in prostate cancer will continue without any protocol changes following a Safety Review Committee assessment, with interim data from nine heavily pre-treated participants showing a favourable safety profile and no renal or ECG toxicity. Efficacy signals are encouraging, with all six participants who had multiple post-treatment PSA assessments experiencing PSA declines, two-thirds achieving at least a 50% reduction and one-third exceeding an 80% reduction, including one patient with bone metastases who reached undetectable PSA and no radiologically detectable disease after three cycles; the company will continue enrolment through 2026 and is progressing plans for a Phase III registrational trial, underscoring the program’s potential to advance in the prostate cancer treatment landscape.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$4.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
Clarity Pharmaceuticals Ltd has notified the market of the cessation of 419,578 options (ASX code CU6AAM) that were due to expire on various dates at various exercise prices. The options lapsed on 31 December 2025 because the conditions attached to these conditional rights were not satisfied or had become incapable of being satisfied, resulting in a reduction of potential future dilution for existing shareholders and a modest simplification of the company’s capital structure.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$3.50 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
Clarity Pharmaceuticals announced that data from its Phase II Co-PSMA investigator-initiated trial of 64Cu-SAR-bisPSMA in men with recurrent prostate cancer have been accepted for an oral presentation at the European Association of Urology Congress 2026, underscoring the scientific importance and visibility of its lead diagnostic agent. The trial demonstrated that 64Cu-SAR-bisPSMA PET/CT detected significantly more, smaller, and earlier lesions than standard-of-care 68Ga-PSMA-11 in patients with low PSA levels, adding to a growing body of clinical and real-world evidence that the product outperforms existing PSMA PET agents and reinforcing Clarity’s positioning as it advances two registrational Phase III trials and targets a share of the expanding multi-billion-dollar PSMA imaging market.
The most recent analyst rating on (AU:CU6) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
Clarity Pharmaceuticals has secured positive guidance from the US Food and Drug Administration to commence a pivotal Phase III registrational trial of its Cu-64 SARTATE PET/CT diagnostic agent in patients with neuroendocrine tumours, with recruitment expected to begin in 2026. The single-arm, open-label trial of around 70 patients aims to generate the data needed to support a US approval filing, building on Phase I and Phase II results showing Cu-64 SARTATE to be safe, well tolerated and substantially more effective at lesion detection, particularly in the liver, than the current standard-of-care Ga-68 DOTATATE. The move marks Clarity’s third registrational trial and underlines the company’s strategy to challenge existing radiopharmaceutical standards with its Targeted Copper Theranostic products, potentially strengthening its position in the rapidly evolving oncology imaging market and offering clinicians improved tools for diagnosing and managing neuroendocrine tumours.
The most recent analyst rating on (AU:CU6) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
Clarity Pharmaceuticals announced the presentation of data from its Phase II DISCO trial at the ASCO Gastrointestinal Cancers Symposium 2026, highlighting the superior diagnostic performance of its 64Cu-SARTATE imaging agent compared to the current standard 68Ga-DOTATATE in detecting neuroendocrine tumors, particularly in the liver. The findings suggest that 64Cu-SARTATE offers significant advantages in sensitivity and accuracy, potentially improving patient outcomes by enabling earlier and more precise disease identification, which is crucial for effective clinical management.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
Clarity Pharmaceuticals Ltd announced the issuance of 34,655 unquoted equity securities under an employee incentive scheme, which are not intended to be quoted on the ASX. This move is part of the company’s strategy to incentivize employees and align their interests with the company’s growth objectives, potentially impacting its operational dynamics and market positioning.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
Clarity Pharmaceuticals Ltd announced the issuance of unquoted equity securities under an employee incentive scheme, with a total of 2,364,776 options expiring on various dates and at various prices. This move is part of the company’s strategy to incentivize its workforce, potentially enhancing its operational capabilities and aligning employee interests with corporate growth objectives.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders in Clarity Pharmaceuticals Ltd., as indicated in their recent notice. This change in holdings could impact Clarity’s market dynamics and shareholder structure, potentially affecting investor confidence and the company’s strategic direction.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
Clarity Pharmaceuticals Ltd announced a change in the director’s interest, with Michelle Parker acquiring additional options as approved at the company’s 2025 Annual General Meeting. This acquisition of options, valued using financial models, reflects strategic decisions that could impact the company’s future financial performance and stakeholder interests.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
Clarity Pharmaceuticals Ltd has announced a change in the director’s interest, with Colin David Biggin acquiring additional options as approved at the company’s 2025 Annual General Meeting. This acquisition involves 487,439 options exercisable at $2.30 each on or before 1 July 2030, reflecting a strategic move to align the director’s interests with the company’s long-term growth objectives. This development highlights the company’s commitment to strengthening its leadership’s stake in its future success, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
Clarity Pharmaceuticals Ltd has announced a change in the director’s interest, with Dr. Alan John Taylor acquiring new options in the company. This acquisition involves a significant number of options, valued using financial models, which may impact the company’s financial standing and reflect strategic positioning in the market. The change in director’s interest could signal confidence in the company’s future performance and influence stakeholder perceptions.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
Clarity Pharmaceuticals Ltd. held its Annual General Meeting where all resolutions, including the remuneration report, re-election of directors, ratification of prior share placements, and the issuance of options to key executives, were carried with significant support. This outcome reflects strong shareholder confidence in the company’s leadership and strategic direction, potentially reinforcing its market position and operational stability.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
Clarity Pharmaceuticals announced at its Annual General Meeting that it has raised $203 million in a recent capital raise, positioning the company strongly in the market. The funds will support ongoing clinical trials, including two Phase III trials for prostate cancer diagnostics, AMPLIFY and CLARIFY, and the development of their SAR-bisPSMA product, which has received three Fast Track Designations from the FDA. The company is also advancing other products in its pipeline, such as SARTATE and SAR-Bombesin, and is exploring new targets through its Discovery Program. Clarity’s strong patent position and focus on science and collaboration are expected to drive future growth and innovation in the oncology market.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
Clarity Pharmaceuticals Ltd presented a general informational update at their Annual General Meeting, emphasizing that the presentation is not a financial product advice or an offer for securities. The company highlighted the speculative nature of investing in their shares and advised potential investors to conduct independent evaluations. The presentation included forward-looking statements, which are based on current assumptions and may not accurately predict future performance, underscoring the inherent risks in the pharmaceutical industry.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
Clarity Pharmaceuticals Ltd. has announced that JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders in the company as of November 19, 2025. This change involves the sale and purchase of ordinary securities by JPMorgan’s subsidiaries, impacting the company’s shareholder structure and potentially influencing its market dynamics.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
Clarity Pharmaceuticals has issued 95,622 fully paid ordinary shares following the exercise of options, without disclosure to investors under the Corporations Act. This move aligns with regulatory compliance and reflects the company’s operational transparency, potentially impacting its market position by enhancing shareholder value.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
Clarity Pharmaceuticals Ltd has announced the quotation of 95,622 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code CU6, effective from November 10, 2025. This move is part of the company’s strategic efforts to enhance its market presence and provide liquidity to its shareholders, potentially strengthening its position in the radiopharmaceutical sector.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
Clarity Pharmaceuticals Ltd. has announced that JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders in the company. This change in holdings involves various transactions by JPMorgan’s subsidiaries, including securities on loan, securities received as collateral, and purchases and sales of securities. The cessation of JPMorgan as a substantial holder may impact Clarity Pharmaceuticals’ shareholder composition and market perception, potentially influencing investor sentiment and the company’s stock performance.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.